生命科学资讯

FDA explains how some copycat drugs can still win three years of exclusivity

EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway

Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up

Theravance ends R&D, lays off 50% of workers after Phase 3 fail

Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

CMS' Chris Klomp on what it will take for AI to succeed in healthcare

Esperion to buy Corstasis and its nasal spray for edema for $75M upfront

Two more members added to ACIP ahead of March meeting

United Therapeutics to take pulmonary hypertension drug to FDA for approval

Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC

Roche gets third pivotal win with MS drug, but liver signal could be a problem

FDA lifts hold on second Intellia Phase 3 gene editing trial

Candid to go public via reverse merger with Rallybio

Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover

UniQure says FDA prefers randomized trial for Huntington's treatment

Novartis' Rhapsido shows promise in Phase 2 food allergy data

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima

GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more

Ascendis wins FDA approval for achondroplasia drug, waits on EU action